JP2023531495A5 - - Google Patents
Info
- Publication number
- JP2023531495A5 JP2023531495A5 JP2022578998A JP2022578998A JP2023531495A5 JP 2023531495 A5 JP2023531495 A5 JP 2023531495A5 JP 2022578998 A JP2022578998 A JP 2022578998A JP 2022578998 A JP2022578998 A JP 2022578998A JP 2023531495 A5 JP2023531495 A5 JP 2023531495A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- isotopolog
- tautomer
- stereoisomer
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063043650P | 2020-06-24 | 2020-06-24 | |
| US63/043,650 | 2020-06-24 | ||
| PCT/US2021/038629 WO2021262815A1 (en) | 2020-06-24 | 2021-06-23 | Cereblon binding compounds, compositions thereof, and methods of treatment therewith |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023531495A JP2023531495A (ja) | 2023-07-24 |
| JP2023531495A5 true JP2023531495A5 (https=) | 2024-06-18 |
| JP7781083B2 JP7781083B2 (ja) | 2025-12-05 |
Family
ID=79167578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022578998A Active JP7781083B2 (ja) | 2020-06-24 | 2021-06-23 | セレブロン結合化合物、その組成物及びそれによる治療方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11560371B2 (https=) |
| EP (1) | EP4171567B1 (https=) |
| JP (1) | JP7781083B2 (https=) |
| KR (1) | KR20230027214A (https=) |
| CN (1) | CN115968293B (https=) |
| AR (1) | AR122726A1 (https=) |
| ES (1) | ES3047718T3 (https=) |
| TW (1) | TW202216690A (https=) |
| WO (1) | WO2021262815A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020405129A1 (en) | 2019-12-19 | 2022-06-23 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| CR20220630A (es) | 2020-05-09 | 2023-01-23 | Arvinas Operations Inc | Métodos para fabricar un compuesto bifuncional, formas ultrapuras del compuesto bifuncional y formas de dosificación que comprenden el mismo |
| JP7778095B2 (ja) | 2020-06-24 | 2025-12-01 | セルジーン コーポレーション | セレブロン結合化合物、その組成物及びそれによる治療方法 |
| KR20230027066A (ko) | 2020-06-24 | 2023-02-27 | 셀진 코포레이션 | 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법 |
| TW202535392A (zh) | 2023-12-08 | 2025-09-16 | 美商亞文納營運公司 | 使用雄性素受體降解劑治療脊髓延髓性肌肉萎縮 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6861432B2 (en) * | 2001-11-23 | 2005-03-01 | Schering Aktiengesellschaft | Piperazine derivatives that destabilize androgen receptors |
| CN101032483B (zh) | 2006-03-09 | 2011-05-04 | 陈德桂 | 调节雄激素受体活性的乙内酰脲衍生物及其应用 |
| JP6817962B2 (ja) * | 2015-01-20 | 2021-01-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | ターゲティングされたアンドロゲン受容体分解のための化合物および方法 |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| CN110023297A (zh) * | 2016-07-08 | 2019-07-16 | 詹森药业有限公司 | 作为雄性激素受体拮抗剂的取代的乙内酰脲和硫代己内酰脲衍生物 |
| CN110317192A (zh) | 2018-03-28 | 2019-10-11 | 上海美志医药科技有限公司 | 一类具有降解雄激素受体活性的化合物 |
| CN113473987B (zh) | 2018-12-19 | 2024-09-03 | 细胞基因公司 | 被取代的3-((3-氨基苯基)氨基)哌啶-2,6-二酮化合物、其组合物和使用其的治疗方法 |
| CN113453681B (zh) | 2018-12-19 | 2024-10-11 | 细胞基因公司 | 经取代的3-((3-氨基苯基)氨基)哌啶-2，6-二酮化合物、其组合物及使用它们的治疗方法 |
| JP7778095B2 (ja) | 2020-06-24 | 2025-12-01 | セルジーン コーポレーション | セレブロン結合化合物、その組成物及びそれによる治療方法 |
| KR20230027066A (ko) | 2020-06-24 | 2023-02-27 | 셀진 코포레이션 | 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법 |
-
2021
- 2021-06-23 KR KR1020237002103A patent/KR20230027214A/ko active Pending
- 2021-06-23 JP JP2022578998A patent/JP7781083B2/ja active Active
- 2021-06-23 AR ARP210101738A patent/AR122726A1/es not_active Application Discontinuation
- 2021-06-23 US US17/356,283 patent/US11560371B2/en active Active
- 2021-06-23 ES ES21829558T patent/ES3047718T3/es active Active
- 2021-06-23 CN CN202180043585.3A patent/CN115968293B/zh active Active
- 2021-06-23 EP EP21829558.2A patent/EP4171567B1/en active Active
- 2021-06-23 WO PCT/US2021/038629 patent/WO2021262815A1/en not_active Ceased
- 2021-06-23 TW TW110122966A patent/TW202216690A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023531709A5 (https=) | ||
| JP2023533203A5 (https=) | ||
| JP2023531495A5 (https=) | ||
| JP2022520448A5 (https=) | ||
| JP2022512482A5 (https=) | ||
| JP2024520481A5 (https=) | ||
| JP2020506951A5 (https=) | ||
| JP2021535207A5 (https=) | ||
| JP2023504147A5 (https=) | ||
| JP2019094345A5 (https=) | ||
| JP2019031560A5 (https=) | ||
| JP2021529812A5 (https=) | ||
| JP2011509309A5 (https=) | ||
| SI2743266T1 (en) | Protein kinase inhibitors (variants), their use in the treatment of oncological diseases and the pharmaceutical composition on their basis | |
| JP2015533782A (ja) | スルファモイル−アリールアミド及びｂ型肝炎の治療のための薬剤としてのその使用 | |
| JP2023536164A5 (https=) | ||
| JP2012528178A5 (https=) | ||
| JP2021502387A5 (https=) | ||
| JP2020507589A5 (https=) | ||
| JP2022511477A5 (https=) | ||
| JP2014528464A5 (https=) | ||
| JP2014520108A5 (https=) | ||
| JP2014514290A5 (https=) | ||
| JP2019507114A5 (https=) | ||
| JP2022514347A5 (https=) |